HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and thei...

Full description

Saved in:
Bibliographic Details
Published inYonsei medical journal Vol. 57; no. 1; pp. 118 - 126
Main Authors Park, Hye Jung, Kim, Young Joo, Kim, Dong Hyun, Kim, Junho, Park, Kyung Hee, Park, Jung-Won, Lee, Jae-Hyun
Format Journal Article
LanguageEnglish
Published Korea (South) Yonsei University College of Medicine 01.01.2016
연세대학교의과대학
Subjects
Online AccessGet full text
ISSN0513-5796
1976-2437
1976-2437
DOI10.3349/ymj.2016.57.1.118

Cover

Loading…
Abstract Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea. We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01. HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03. HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
AbstractList Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneousadverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea. Materials and Methods: We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01. Results: HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessedHLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12–463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03–157.14; p=0.053). Among carbamazepine users, only two patients experiencedSJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03. Conclusion: HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN. KCI Citation Count: 16
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea. We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01. HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03. HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea.PURPOSEStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea.We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01.MATERIALS AND METHODSWe enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01.HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03.RESULTSHLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessed HLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12-463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03-157.14; p=0.053). Among carbamazepine users, only two patients experienced SJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03.HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.CONCLUSIONHLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
Author Kim, Young Joo
Park, Jung-Won
Park, Hye Jung
Lee, Jae-Hyun
Kim, Junho
Kim, Dong Hyun
Park, Kyung Hee
AuthorAffiliation Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Hye Jung
  surname: Park
  fullname: Park, Hye Jung
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Young Joo
  surname: Kim
  fullname: Kim, Young Joo
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Dong Hyun
  surname: Kim
  fullname: Kim, Dong Hyun
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Junho
  surname: Kim
  fullname: Kim, Junho
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Kyung Hee
  surname: Park
  fullname: Park, Kyung Hee
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Jung-Won
  surname: Park
  fullname: Park, Jung-Won
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Jae-Hyun
  surname: Lee
  fullname: Lee, Jae-Hyun
  organization: Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26632391$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002059294$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kUtvEzEUhS1URNPCD2CDvGQzqa89tmdYII1CXxCBRANby_F4UrcTO9gzoPz7Og3hJbG6kv2dc659TtCRD94i9BLIlLGyPtuu76aUgJhyOYUpQPUETaCWoqAlk0doQjiwgstaHKOTlO4IoRIIfYaOqRCMshomyF_NG9z0ve0tvoj222i9cTZh5zGvCMUfQrTapzf4q47Otgd0sd1kqEkpGKeHfP7DDbf45v3N2eL8I26MCbF1foWHgGdjv4luwO_iuErP0dNO98m--DlP0ZeL88Xsqph_uryeNfPClIwORdXKlstWwLKuJKOUi67lIABIlZ-2tBREBbTWlkgquOnkkhBdVtLUBnRVCXaKXu99fezUvXEqaPc4V0HdR9V8XlwrxsgefbtHN-NybVtj_RB1r_LOax23j8K_b7y7zTbfVSlqUZf0d9Ymhvx_aVBrl4zte-1tGJMCWZaC18BZRl_9mfUr5NBHBuQeMDGkFG2njBv04MIu2vUKiNo1r3Lzate84lKBys1nJfyjPJj_X_MAgJOvXg
CitedBy_id crossref_primary_10_1038_s43018_023_00561_8
crossref_primary_10_17816_dv625526
crossref_primary_10_3341_jkos_2021_62_6_842
crossref_primary_10_15263_jlmqa_2024_46_1_1
crossref_primary_10_3390_diagnostics11091611
crossref_primary_10_1186_s13321_017_0202_6
crossref_primary_10_1002_jcph_2040
crossref_primary_10_1007_s00403_021_02258_3
crossref_primary_10_1136_bjophthalmol_2020_317105
crossref_primary_10_1016_j_iac_2022_01_006
crossref_primary_10_1038_s12276_023_00952_y
crossref_primary_10_1097_FPC_0000000000000397
crossref_primary_10_1016_j_jaip_2019_05_047
crossref_primary_10_1371_journal_pone_0296498
crossref_primary_10_12688_f1000research_24748_1
crossref_primary_10_1016_j_coi_2016_05_003
crossref_primary_10_1016_j_trim_2023_101859
crossref_primary_10_1111_1346_8138_17692
crossref_primary_10_1186_s13321_018_0257_z
crossref_primary_10_3389_fphar_2022_891838
crossref_primary_10_1097_ACI_0000000000000914
crossref_primary_10_1002_stem_2865
crossref_primary_10_1097_CM9_0000000000003250
crossref_primary_10_18632_oncotarget_13250
crossref_primary_10_1016_j_bbmt_2020_05_008
crossref_primary_10_1186_s13023_017_0566_8
crossref_primary_10_1007_s12016_017_8654_z
crossref_primary_10_1016_j_braindev_2018_05_005
crossref_primary_10_2217_pgs_2021_0041
crossref_primary_10_1016_j_seizure_2021_07_011
crossref_primary_10_1097_FPC_0000000000000531
crossref_primary_10_3389_fimmu_2021_661135
crossref_primary_10_1016_j_heliyon_2024_e33976
crossref_primary_10_1002_pds_4774
crossref_primary_10_3389_fmed_2023_1238405
crossref_primary_10_1080_14740338_2020_1796965
crossref_primary_10_1007_s12687_024_00753_4
crossref_primary_10_3389_fmed_2021_640360
crossref_primary_10_2217_pme_2022_0126
crossref_primary_10_12793_tcp_2016_24_3_143
crossref_primary_10_15324_kjcls_2024_56_3_236
crossref_primary_10_1111_jdv_16339
crossref_primary_10_1186_s13046_021_02034_1
crossref_primary_10_12677_acm_2024_1492540
crossref_primary_10_5483_BMBRep_2022_55_9_077
crossref_primary_10_3389_fphar_2017_00879
crossref_primary_10_1111_jcpt_13616
crossref_primary_10_1016_j_jhep_2019_03_018
crossref_primary_10_3349_ymj_2019_60_2_208
crossref_primary_10_3389_fphar_2024_1423636
crossref_primary_10_1097_FPC_0000000000000306
crossref_primary_10_1002_advs_202409919
crossref_primary_10_3389_fmed_2021_644871
Cites_doi 10.1111/j.1365-2133.2012.10894.x
10.1111/j.1346-8138.2010.01196.x
10.1097/01.bor.0000209435.89720.7c
10.1007/s00134-009-1659-1
10.1038/clpt.2012.189
10.1093/ndt/gfr060
10.1007/978-1-61779-842-9_4
10.3343/kjlm.2010.30.6.685
10.1038/jid.2012.510
10.2217/pgs.11.165
10.1016/j.jaci.2011.12.990
10.1038/nature11147
10.1016/j.eplepsyres.2010.10.006
10.1016/j.eplepsyres.2011.08.010
10.1016/S0300-2977(97)00088-0
10.3349/ymj.2015.56.2.578
10.1111/j.1742-7843.2011.00681.x
10.2217/pgs.09.162
10.1001/archderm.1993.01680220104023
10.1136/adc.2010.190454
10.1159/000335612
10.1038/sj.jid.5701033
10.12788/j.sder.0058
10.1016/j.jaad.2007.08.036
10.1016/j.humimm.2012.07.321
10.1097/FPC.0b013e32832c347d
10.2217/pgs.12.89
10.1097/FPC.0b013e328330a3b8
10.1111/iji.12067
10.1186/1471-2377-13-77
10.1097/ACI.0b013e3282370c5f
10.2217/pgs.10.77
10.1002/acr.21772
10.1038/tpj.2013.40
10.1093/hmg/ddq537
10.1097/FPC.0b013e3282f3ef9c
10.1007/s00228-014-1764-0
10.1097/FPC.0b013e32834282b8
10.1111/j.1399-0039.2005.00386.x
ContentType Journal Article
Copyright Copyright: Yonsei University College of Medicine 2016 2016
Copyright_xml – notice: Copyright: Yonsei University College of Medicine 2016 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3349/ymj.2016.57.1.118
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1976-2437
EndPage 126
ExternalDocumentID oai_kci_go_kr_ARTI_330886
PMC4696942
26632391
10_3349_ymj_2016_57_1_118
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Republic of Korea
GeographicLocations_xml – name: Republic of Korea
GrantInformation_xml – fundername: ;
GroupedDBID ---
.55
.GJ
123
29R
2WC
36B
5-W
53G
5RE
8JR
8XY
9ZL
AAYXX
ACYCR
ADBBV
ADRAZ
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
CS3
DIK
DU5
E3Z
EBD
EF.
EMB
EMOBN
F5P
GROUPED_DOAJ
GX1
HYE
KQ8
L7B
M48
MK0
O5R
O5S
OK1
OVT
P2P
PGMZT
RNS
RPM
SV3
TR2
X7M
XSB
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c432t-8d7d57d61b98732256fd5161108243be2168129ae07265cf7b00a487c9c1a8863
IEDL.DBID M48
ISSN 0513-5796
1976-2437
IngestDate Sun Mar 09 07:50:53 EDT 2025
Thu Aug 21 17:52:13 EDT 2025
Fri Jul 11 04:59:40 EDT 2025
Mon Jul 21 06:01:12 EDT 2025
Tue Jul 01 04:03:00 EDT 2025
Thu Apr 24 23:03:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Stevens-Johnson syndrome
HLA-B58:01
human leukocyte antigen
Allopurinol
toxic epidermal necrolysis
Language English
License http://creativecommons.org/licenses/by-nc/3.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c432t-8d7d57d61b98732256fd5161108243be2168129ae07265cf7b00a487c9c1a8863
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Hye Jung Park and Young Joo Kim contributed equally to this work.
http://ymj.kr/DOIx.php?id=10.3349/ymj.2016.57.1.118
G704-000409.2016.57.1.007
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2016.57.1.118
PMID 26632391
PQID 1744659153
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_330886
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4696942
proquest_miscellaneous_1744659153
pubmed_primary_26632391
crossref_citationtrail_10_3349_ymj_2016_57_1_118
crossref_primary_10_3349_ymj_2016_57_1_118
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Yonsei medical journal
PublicationTitleAlternate Yonsei Med J
PublicationYear 2016
Publisher Yonsei University College of Medicine
연세대학교의과대학
Publisher_xml – name: Yonsei University College of Medicine
– name: 연세대학교의과대학
References Kim (10.3349/ymj.2016.57.1.118_ref16) 2011; 97
Struck (10.3349/ymj.2016.57.1.118_ref2) 2010; 36
Illing (10.3349/ymj.2016.57.1.118_ref7) 2012; 486
Chung (10.3349/ymj.2016.57.1.118_ref32) 2007; 7
Park (10.3349/ymj.2016.57.1.118_ref13) 2015; 71
Wei (10.3349/ymj.2016.57.1.118_ref6) 2012; 129
Mockenhaupt (10.3349/ymj.2016.57.1.118_ref21) 2014; 33
Sekula (10.3349/ymj.2016.57.1.118_ref4) 2013; 133
Ganesan (10.3349/ymj.2016.57.1.118_ref11) 2011; 96
Lee (10.3349/ymj.2016.57.1.118_ref40) 2005; 65
Phillips (10.3349/ymj.2016.57.1.118_ref24) 2009; 11
Hung (10.3349/ymj.2016.57.1.118_ref14) 2010; 11
Mockenhaupt (10.3349/ymj.2016.57.1.118_ref1) 2012; 97
Yip (10.3349/ymj.2016.57.1.118_ref35) 2012; 92
An (10.3349/ymj.2016.57.1.118_ref39) 2010; 92
Chung (10.3349/ymj.2016.57.1.118_ref19) 2010; 30
Kazeem (10.3349/ymj.2016.57.1.118_ref36) 2009; 19
Shi (10.3349/ymj.2016.57.1.118_ref38) 2011; 109
Ozeki (10.3349/ymj.2016.57.1.118_ref34) 2011; 20
Bastuji-Garin (10.3349/ymj.2016.57.1.118_ref3) 1993; 129
Halevy (10.3349/ymj.2016.57.1.118_ref30) 2008; 58
Huh (10.3349/ymj.2016.57.1.118_ref18) 2013; 40
Mockenhaupt (10.3349/ymj.2016.57.1.118_ref5) 2008; 128
Genin (10.3349/ymj.2016.57.1.118_ref12) 2014; 14
Phillips (10.3349/ymj.2016.57.1.118_ref25) 2010; 11
Tassaneeyakul (10.3349/ymj.2016.57.1.118_ref33) 2009; 19
Park (10.3349/ymj.2016.57.1.118_ref27) 2015; 56
Pluim (10.3349/ymj.2016.57.1.118_ref29) 1998; 52
Khanna (10.3349/ymj.2016.57.1.118_ref31) 2012; 64
Cao (10.3349/ymj.2016.57.1.118_ref8) 2012; 13
McCormack (10.3349/ymj.2016.57.1.118_ref37) 2012; 13
Trajanoski (10.3349/ymj.2016.57.1.118_ref20) 2012; 882
Dong (10.3349/ymj.2016.57.1.118_ref23) 2012; 73
Chiu (10.3349/ymj.2016.57.1.118_ref9) 2012; 167
Kang (10.3349/ymj.2016.57.1.118_ref17) 2011; 21
Lonjou (10.3349/ymj.2016.57.1.118_ref10) 2008; 18
Jung (10.3349/ymj.2016.57.1.118_ref15) 2011; 26
Aihara (10.3349/ymj.2016.57.1.118_ref26) 2011; 38
Mikuls (10.3349/ymj.2016.57.1.118_ref28) 2006; 18
Balnyte (10.3349/ymj.2016.57.1.118_ref22) 2013; 13
23132554 - Clin Pharmacol Ther. 2012 Dec;92(6):757-65
23724919 - Int J Immunogenet. 2013 Dec;40(6):515-23
21157157 - Korean J Lab Med. 2010 Dec;30(6):685-96
22613850 - Chem Immunol Allergy. 2012;97:1-17
25327504 - Eur J Clin Pharmacol. 2015 Jan;71(1):35-41
20602616 - Pharmacogenomics. 2010 Jul;11(7):973-87
22379998 - Pharmacogenomics. 2012 Mar;13(4):399-405
19787334 - Intensive Care Med. 2010 Jan;36(1):22-32
21301380 - Pharmacogenet Genomics. 2011 May;21(5):303-7
21917426 - Epilepsy Res. 2011 Nov;97(1-2):190-7
22322005 - J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5
20235791 - Pharmacogenomics. 2010 Mar;11(3):349-56
21393610 - Nephrol Dial Transplant. 2011 Nov;26(11):3567-72
22841927 - Hum Immunol. 2012 Oct;73(10):998-1004
17919772 - J Am Acad Dermatol. 2008 Jan;58(1):25-32
8420497 - Arch Dermatol. 1993 Jan;129(1):92-6
21342226 - J Dermatol. 2011 Mar;38(3):246-54
19668019 - Pharmacogenet Genomics. 2009 Sep;19(9):661-5
21149285 - Hum Mol Genet. 2011 Mar 1;20(5):1034-41
21306565 - Basic Clin Pharmacol Toxicol. 2011 Jul;109(1):42-6
23389396 - J Invest Dermatol. 2013 May;133(5):1197-204
9599967 - Neth J Med. 1998 Mar;52(3):107-10
15853898 - Tissue Antigens. 2005 May;65(5):437-47
22665228 - Methods Mol Biol. 2012;882:47-65
25037254 - Semin Cutan Med Surg. 2014 Mar;33(1):10-6
21169235 - Arch Dis Child. 2011 Jan;96(1):104-6
23837503 - BMC Neurol. 2013;13:77
17620823 - Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23
21071176 - Epilepsy Res. 2010 Dec;92(2-3):226-30
16462529 - Curr Opin Rheumatol. 2006 Mar;18(2):199-203
19479656 - Curr Opin Mol Ther. 2009 Jun;11(3):231-42
18192896 - Pharmacogenet Genomics. 2008 Feb;18(2):99-107
22348415 - Br J Dermatol. 2012 Jul;167(1):44-9
22722860 - Nature. 2012 Jun 28;486(7404):554-8
22909208 - Pharmacogenomics. 2012 Jul;13(10):1193-201
25684012 - Yonsei Med J. 2015 Mar;56(2):578-81
19696695 - Pharmacogenet Genomics. 2009 Sep;19(9):704-9
23024028 - Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46
17805350 - J Invest Dermatol. 2008 Jan;128(1):35-44
24322785 - Pharmacogenomics J. 2014 Jun;14(3):281-8
References_xml – volume: 167
  start-page: 44
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref9
  publication-title: Br J Dermatol
  doi: 10.1111/j.1365-2133.2012.10894.x
– volume: 38
  start-page: 246
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref26
  publication-title: J Dermatol
  doi: 10.1111/j.1346-8138.2010.01196.x
– volume: 18
  start-page: 199
  year: 2006
  ident: 10.3349/ymj.2016.57.1.118_ref28
  publication-title: Curr Opin Rheumatol
  doi: 10.1097/01.bor.0000209435.89720.7c
– volume: 36
  start-page: 22
  year: 2010
  ident: 10.3349/ymj.2016.57.1.118_ref2
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-009-1659-1
– volume: 92
  start-page: 757
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref35
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.189
– volume: 26
  start-page: 3567
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref15
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfr060
– volume: 882
  start-page: 47
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref20
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-61779-842-9_4
– volume: 30
  start-page: 685
  year: 2010
  ident: 10.3349/ymj.2016.57.1.118_ref19
  publication-title: Korean J Lab Med
  doi: 10.3343/kjlm.2010.30.6.685
– volume: 133
  start-page: 1197
  year: 2013
  ident: 10.3349/ymj.2016.57.1.118_ref4
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2012.510
– volume: 13
  start-page: 399
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref37
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.11.165
– volume: 129
  start-page: 1562
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref6
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2011.12.990
– volume: 486
  start-page: 554
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref7
  publication-title: Nature
  doi: 10.1038/nature11147
– volume: 92
  start-page: 226
  year: 2010
  ident: 10.3349/ymj.2016.57.1.118_ref39
  publication-title: Epilepsy Res
  doi: 10.1016/j.eplepsyres.2010.10.006
– volume: 97
  start-page: 190
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref16
  publication-title: Epilepsy Res
  doi: 10.1016/j.eplepsyres.2011.08.010
– volume: 52
  start-page: 107
  year: 1998
  ident: 10.3349/ymj.2016.57.1.118_ref29
  publication-title: Neth J Med
  doi: 10.1016/S0300-2977(97)00088-0
– volume: 56
  start-page: 578
  year: 2015
  ident: 10.3349/ymj.2016.57.1.118_ref27
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2015.56.2.578
– volume: 109
  start-page: 42
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref38
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/j.1742-7843.2011.00681.x
– volume: 11
  start-page: 349
  year: 2010
  ident: 10.3349/ymj.2016.57.1.118_ref14
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.09.162
– volume: 129
  start-page: 92
  year: 1993
  ident: 10.3349/ymj.2016.57.1.118_ref3
  publication-title: Arch Dermatol
  doi: 10.1001/archderm.1993.01680220104023
– volume: 11
  start-page: 231
  year: 2009
  ident: 10.3349/ymj.2016.57.1.118_ref24
  publication-title: Curr Opin Mol Ther
– volume: 96
  start-page: 104
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref11
  publication-title: Arch Dis Child
  doi: 10.1136/adc.2010.190454
– volume: 97
  start-page: 1
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref1
  publication-title: Chem Immunol Allergy
  doi: 10.1159/000335612
– volume: 128
  start-page: 35
  year: 2008
  ident: 10.3349/ymj.2016.57.1.118_ref5
  publication-title: J Invest Dermatol
  doi: 10.1038/sj.jid.5701033
– volume: 33
  start-page: 10
  year: 2014
  ident: 10.3349/ymj.2016.57.1.118_ref21
  publication-title: Semin Cutan Med Surg
  doi: 10.12788/j.sder.0058
– volume: 58
  start-page: 25
  year: 2008
  ident: 10.3349/ymj.2016.57.1.118_ref30
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2007.08.036
– volume: 73
  start-page: 998
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref23
  publication-title: Hum Immunol
  doi: 10.1016/j.humimm.2012.07.321
– volume: 19
  start-page: 661
  year: 2009
  ident: 10.3349/ymj.2016.57.1.118_ref36
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32832c347d
– volume: 13
  start-page: 1193
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref8
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.12.89
– volume: 19
  start-page: 704
  year: 2009
  ident: 10.3349/ymj.2016.57.1.118_ref33
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e328330a3b8
– volume: 40
  start-page: 515
  year: 2013
  ident: 10.3349/ymj.2016.57.1.118_ref18
  publication-title: Int J Immunogenet
  doi: 10.1111/iji.12067
– volume: 13
  start-page: 77
  year: 2013
  ident: 10.3349/ymj.2016.57.1.118_ref22
  publication-title: BMC Neurol
  doi: 10.1186/1471-2377-13-77
– volume: 7
  start-page: 317
  year: 2007
  ident: 10.3349/ymj.2016.57.1.118_ref32
  publication-title: Curr Opin Allergy Clin Immunol
  doi: 10.1097/ACI.0b013e3282370c5f
– volume: 11
  start-page: 973
  year: 2010
  ident: 10.3349/ymj.2016.57.1.118_ref25
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.77
– volume: 64
  start-page: 1431
  year: 2012
  ident: 10.3349/ymj.2016.57.1.118_ref31
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.21772
– volume: 14
  start-page: 281
  year: 2014
  ident: 10.3349/ymj.2016.57.1.118_ref12
  publication-title: Pharmacogenomics J
  doi: 10.1038/tpj.2013.40
– volume: 20
  start-page: 1034
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref34
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddq537
– volume: 18
  start-page: 99
  year: 2008
  ident: 10.3349/ymj.2016.57.1.118_ref10
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3282f3ef9c
– volume: 71
  start-page: 35
  year: 2015
  ident: 10.3349/ymj.2016.57.1.118_ref13
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-014-1764-0
– volume: 21
  start-page: 303
  year: 2011
  ident: 10.3349/ymj.2016.57.1.118_ref17
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32834282b8
– volume: 65
  start-page: 437
  year: 2005
  ident: 10.3349/ymj.2016.57.1.118_ref40
  publication-title: Tissue Antigens
  doi: 10.1111/j.1399-0039.2005.00386.x
– reference: 17919772 - J Am Acad Dermatol. 2008 Jan;58(1):25-32
– reference: 21917426 - Epilepsy Res. 2011 Nov;97(1-2):190-7
– reference: 23024028 - Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46
– reference: 25684012 - Yonsei Med J. 2015 Mar;56(2):578-81
– reference: 23389396 - J Invest Dermatol. 2013 May;133(5):1197-204
– reference: 23724919 - Int J Immunogenet. 2013 Dec;40(6):515-23
– reference: 19696695 - Pharmacogenet Genomics. 2009 Sep;19(9):704-9
– reference: 22841927 - Hum Immunol. 2012 Oct;73(10):998-1004
– reference: 22379998 - Pharmacogenomics. 2012 Mar;13(4):399-405
– reference: 21342226 - J Dermatol. 2011 Mar;38(3):246-54
– reference: 19668019 - Pharmacogenet Genomics. 2009 Sep;19(9):661-5
– reference: 21149285 - Hum Mol Genet. 2011 Mar 1;20(5):1034-41
– reference: 19787334 - Intensive Care Med. 2010 Jan;36(1):22-32
– reference: 20602616 - Pharmacogenomics. 2010 Jul;11(7):973-87
– reference: 22722860 - Nature. 2012 Jun 28;486(7404):554-8
– reference: 25327504 - Eur J Clin Pharmacol. 2015 Jan;71(1):35-41
– reference: 25037254 - Semin Cutan Med Surg. 2014 Mar;33(1):10-6
– reference: 22348415 - Br J Dermatol. 2012 Jul;167(1):44-9
– reference: 21306565 - Basic Clin Pharmacol Toxicol. 2011 Jul;109(1):42-6
– reference: 17620823 - Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23
– reference: 21071176 - Epilepsy Res. 2010 Dec;92(2-3):226-30
– reference: 8420497 - Arch Dermatol. 1993 Jan;129(1):92-6
– reference: 9599967 - Neth J Med. 1998 Mar;52(3):107-10
– reference: 21301380 - Pharmacogenet Genomics. 2011 May;21(5):303-7
– reference: 23132554 - Clin Pharmacol Ther. 2012 Dec;92(6):757-65
– reference: 15853898 - Tissue Antigens. 2005 May;65(5):437-47
– reference: 21393610 - Nephrol Dial Transplant. 2011 Nov;26(11):3567-72
– reference: 17805350 - J Invest Dermatol. 2008 Jan;128(1):35-44
– reference: 21157157 - Korean J Lab Med. 2010 Dec;30(6):685-96
– reference: 22665228 - Methods Mol Biol. 2012;882:47-65
– reference: 19479656 - Curr Opin Mol Ther. 2009 Jun;11(3):231-42
– reference: 21169235 - Arch Dis Child. 2011 Jan;96(1):104-6
– reference: 22613850 - Chem Immunol Allergy. 2012;97:1-17
– reference: 22909208 - Pharmacogenomics. 2012 Jul;13(10):1193-201
– reference: 18192896 - Pharmacogenet Genomics. 2008 Feb;18(2):99-107
– reference: 20235791 - Pharmacogenomics. 2010 Mar;11(3):349-56
– reference: 22322005 - J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5
– reference: 16462529 - Curr Opin Rheumatol. 2006 Mar;18(2):199-203
– reference: 23837503 - BMC Neurol. 2013;13:77
– reference: 24322785 - Pharmacogenomics J. 2014 Jun;14(3):281-8
SSID ssj0027102
Score 2.3349533
Snippet Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneous adverse reaction. SJS/TEN induced by...
Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneousadverse reaction. SJS/TEN induced...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 118
SubjectTerms Adult
Aged
Alleles
Allopurinol - adverse effects
Allopurinol - pharmacology
Anticonvulsants - adverse effects
Asian Continental Ancestry Group - genetics
Carbamazepine - adverse effects
Carbamazepine - pharmacology
Case-Control Studies
Drug-Related Side Effects and Adverse Reactions - genetics
Drug-Related Side Effects and Adverse Reactions - immunology
Female
Gene Frequency
Genetic Predisposition to Disease
Genotype
HLA-B Antigens - genetics
Humans
Male
Middle Aged
Odds Ratio
Original
Polymorphism, Single Nucleotide
Republic of Korea
Retrospective Studies
Risk Factors
Stevens-Johnson Syndrome - ethnology
Stevens-Johnson Syndrome - etiology
Stevens-Johnson Syndrome - genetics
Triazines - adverse effects
Triazines - pharmacology
의학일반
Title HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs
URI https://www.ncbi.nlm.nih.gov/pubmed/26632391
https://www.proquest.com/docview/1744659153
https://pubmed.ncbi.nlm.nih.gov/PMC4696942
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002059294
Volume 57
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Yonsei Medical Journal, 2016, 57(1), , pp.118-126
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLbWISFe0MZt3VhlJJ6Q0tWJb0FCqBqrymB72Qp7s3JxR1lwtiSV2L_nnFwKRRUST1ESJ1b8-eR8ny_nEPJaRkGaAG_wtI_TjJb7Xox7ZRJuRyqdyzRI6mif53I646dX4mqLdOmt2gYsN0o7zCc1K7Lhz7v792Dw71BxBjw8uv_xHddoyaFQQwb_AN0jD8AxKczkcMb1b_3F6iWI0A0DD7dgNpOcm1-x5qZ6rphvYqB_L6T8wzNNdsjjllLScdMHdsmWdU_Iw7N20vwpcdPPYzrOMnAwdFI0S6dBH9OFo0KPfPopB-Loyrf0C-rmtCuKCrWkHXxwHYds6cXpxdHlyTnFLBMF-j1a5fR4md0Wi4p-KJbX5TMym5xcHk-9Ns0CABL4ladTlQqVShaHWqF9y3kqgAgyYAc8iK3PMEZZGAF4vhTJXIGlRqBzkjBhkdYyeE62Xe7sHqFaxdZGDKMKjniQAHtUQJdEaP0YjV31yahrVZO0McgxFUZmQIsgEAaAMAiEEcowkCe6T96sHrltAnD8q_ArgMrcJAuDYbPxeJ2bm8KAOPgIz8AvVUKZDkgDpoTzI5Gz-bI0IM64FCH4gD550QC7qhJ4TAC9mfWJWoN8VQDrW7_jFt_qcN1chjLk_v7_fMgBeYTnzVjPS7JdFUt7COynigekJ7yvg3rsYFD371_Su_6n
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA+Allele+Frequencies+in+5802+Koreans%3A+Varied+Allele+Types+Associated+with+SJS%2FTEN+According+to+Culprit+Drugs&rft.jtitle=Yonsei+medical+journal&rft.au=Park%2C+Hye+Jung&rft.au=Kim%2C+Young+Joo&rft.au=Kim%2C+Dong+Hyun&rft.au=Kim%2C+Junho&rft.date=2016-01-01&rft.issn=0513-5796&rft.eissn=1976-2437&rft.volume=57&rft.issue=1&rft.spage=118&rft_id=info:doi/10.3349%2Fymj.2016.57.1.118&rft.externalDBID=n%2Fa&rft.externalDocID=10_3349_ymj_2016_57_1_118
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon